Remembering the Maryland residents who died from coronavirus baltimoresun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baltimoresun.com Daily Mail and Mail on Sunday newspapers.
Low Demand For Antibody Drugs Against COVID-19
Update RequiredTo play audio, update browser or Flash plugin.
President Trump boards Marine One for a trip from the White House to Walter Reed National Military Medical Center for COVID-19 treatment in early October. Trump received Regeneron s antibody cocktail during his illness.
Alex Brandon / AP
Federal officials are disappointed to find that the monoclonal antibody drugs they ve shipped across the country aren t being used rapidly.
These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the hospital. But hospitals are finding it cumbersome to use these medicines, which must be given by IV infusion. And some patients and doctors are lukewarm about drugs that have an uncertain benefit.
/
President Trump boards Marine One for a trip from the White House to Walter Reed National Military Medical Center for COVID-19 treatment in early October. Trump received Regeneron s antibody cocktail during his illness. // AP, Alex Brandon
Federal officials are disappointed to find that the monoclonal antibody drugs they ve shipped across the country aren t being used rapidly.
These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the hospital. But hospitals are finding it cumbersome to use these medicines, which must be given by IV infusion. And some patients and doctors are lukewarm about drugs that have an uncertain benefit.
Alex Brandon/AP
toggle caption Alex Brandon/AP
President Trump boards Marine One for a trip from the White House to Walter Reed National Military Medical Center for COVID-19 treatment in early October. Trump received Regeneron s antibody cocktail during his illness. Alex Brandon/AP
Federal officials are disappointed to find that the monoclonal antibody drugs they ve shipped across the country aren t being used rapidly.
These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the hospital. But hospitals are finding it cumbersome to use these medicines, which must be given by IV infusion. And some patients and doctors are lukewarm about drugs that have an uncertain benefit.
Low Demand For Antibody Drugs Against COVID-19
Federal officials are disappointed to find that the monoclonal antibody drugs they ve shipped across the country aren t being used rapidly.
These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the hospital. But hospitals are finding it cumbersome to use these medicines, which must be given by IV infusion. And some patients and doctors are lukewarm about drugs that have an uncertain benefit.
The Food and Drug Administration granted emergency authorization in November to two monoclonal antibody products â one produced by Eli Lilly, the other by Regeneron. President Trump was given the Regeneron product on an emergency basis before the FDA authorized it for widespread use.